Top

Published in:

01-06-2014 | Brief Report

IGRA-positive patients and interferon-gamma/interleukin-2 signatures: Can the Fluorospot assay provide further information?

Authors: P. Bittel, D. Mayor, P. Iseli, T. Bodmer, F. Suter-Riniker

Published in: Infection | Issue 3/2014

Abstract

A goal of testing for latent tuberculosis (TB) infection is to identify individuals who are at increased risk for the development of active TB. No laboratory tool is currently available to distinguish between individuals in the process of progressing from latent TB infection towards active disease and those who are not. Determination of the interferon-gamma and interleukin-2 T cell signature might provide an additional and rapid tool to evaluate treatment necessity and clinical management of a patient. Here, we present three cases of interferon-gamma release assay-positive patients with differing interferon-gamma and interleukin-2 signatures when analyzed by the Fluorospot assay.

O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol. 2013;31:475–527. doi:10.1146/annurev-immunol-032712-095939.PubMedCrossRef

Schablon A, Harling M, Diel R, Nienhaus A. Risk of latent TB infection in individuals employed in the healthcare sector in Germany: a multicentre prevalence study. BMC Infect Dis. 2010;10:107. doi:10.1186/1471-2334-10-107.PubMedCentralPubMedCrossRef

Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.PubMedCentralPubMedCrossRef

Nienhaus A, Schablon A, Costa JT, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011;11:247. doi:10.1186/1472-6963-11-247.PubMedCentralPubMedCrossRef

Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest. 2012;142:63–75. doi:10.1378/chest.11-3157.PubMedCrossRef

Rubbo PA, Nagot N, Le Moing V, Brabet M, Bourdin A, Nogue E, et al. Multicytokine detection improves latent tuberculosis diagnosis in health care workers. J Clin Microbiol. 2012;50:1711–7. doi:10.1128/JCM.00117-12.PubMedCentralPubMedCrossRef

Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol. 2006;6:417–23. doi:10.1038/nri1840.PubMedCrossRef

Millington KA, Innes JA, Hackforth S, Hinks TS, Deeks JJ, Dosanjh DP, et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol. 2007;178:5217–26.PubMedCentralPubMedCrossRef

Casey R, Blumenkrantz D, Millington K, Montamat-Sicotte D, Kon OM, Wickremasinghe M, et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS ONE. 2010;5:e15619. doi:10.1371/journal.pone.0015619.PubMedCentralPubMedCrossRef

10.

Suter-Riniker F, Berger A, Mayor D, Bittel P, Iseli P, Bodmer T. Clinical significance of interleukin-2/gamma interferon ratios in mycobacterium tuberculosis-specific T-cell signatures. Clin Vaccine Immunol. 2011;18:1395–6. doi:10.1128/CVI.05013-11.PubMedCentralPubMedCrossRef

11.

Quast S, Zhang W, Shive C, Kovalovski D, Ott PA, Herzog BA, et al. IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. Cell Immunol. 2005;237:28–36. doi:10.1016/j.cellimm.2005.09.002.PubMedCrossRef

12.

Ringshausen FC, Nienhaus A, Torres Costa J, Knoop H, Schlosser S, Schultze-Werninghaus G, et al. Within-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses in German health care workers. Clin Vaccine Immunol. 2011;18:1176–82. doi:10.1128/CVI.05058-11.PubMedCentralPubMedCrossRef

13.

Kim SY, Park MS, Kim YS, Kim SK, Chang J, Kang YA. Conversion rates of an interferon-gamma release assay and the tuberculin skin test in the serial monitoring of healthcare workers. Infection. 2013;41:511–6. doi:10.1007/s15010-012-0356-0.PubMedCrossRef

14.

Cavalcanti YV, Brelaz MC, Neves JK, Ferraz JC, Pereira VR. Role of TNF-Alpha, IFN-Gamma, and IL-10 in the development of pulmonary tuberculosis. Pulm Med. 2012;2012:745483. doi:10.1155/2012/745483.PubMedCentralPubMedCrossRef

Title: IGRA-positive patients and interferon-gamma/interleukin-2 signatures: Can the Fluorospot assay provide further information?
Authors: P. Bittel
D. Mayor
P. Iseli
T. Bodmer
F. Suter-Riniker
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: Infection / Issue 3/2014
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-014-0588-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

IGRA-positive patients and interferon-gamma/interleukin-2 signatures: Can the Fluorospot assay provide further information?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Characteristics and treatment outcomes of 69 cases with early prosthetic joint infections of the hip and knee

Emergence of Klebsiella pneumoniae liver abscesses in South-western Sydney

Tolerance and safety of intravenous streptomycin therapy in patients with tuberculosis

Effect of empiric antibiotic treatment on plasma endotoxin activity in septic patients

Outcome-related co-factors in 105 cases of vertebral osteomyelitis in a tertiary care hospital

Chronic necrotizing pulmonary aspergillosis in an immunocompetent patient: report of a rare case

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page